Voxilaprevir
Voxilaprevir is a pan-genotypic nonstructural protein 3/4A (NS3/4A) protease inhibitor that blocks HCV protease-mediated cleavage of the viral polyprotein, preventing replication of all major hepatitis C virus genotypes. It is used in combination with sofosbuvir and velpatasvir (Vosevi) for treatment of HCV infection across genotypes 1-6, particularly in patients who have failed prior DAA therapy. Its pan-genotypic protease inhibition activity complements NS5A and NS5B inhibitors for complete HCV lifecycle blockade.
Berat Molekul
868,9000 g/mol
LogP
5,90
TPSA
204,00 Ų
Lipinski RO5
Gagal
Area Terapeutik
Mekanisme Kerja
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CC[C@@H]1[C@@H]2CN(C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]3C[C@H]3CCCCC(F)(F)c3nc4ccc(OC)cc4nc3O2)[C@@H]1C(=O)N[C@]1(C(=O)NS(=O)(=O)C2(C)CC2)C[C@H]1C(C)C
InChI
InChI=1S/C42H58F2N6O9S/c1-9-25-30-21-50(31(25)34(51)48-41(20-26(41)22(2)3)37(53)49-60(55,56)40(7)16-17-40)36(52)33(39(4,5)6)47-38(54)59-29-18-23(29)12-10-11-15-42(43,44)32-35(58-30)46-28-19-24(57-8)13-14-27(28)45-32/h13-14,19,22-23,25-26,29-31,33H,9-12,15-18,20-21H2,1-8H3,(H,47,54)(H,48,51)(H,49,53)/t23-,25-,26+,29-,30+,31+,33-,41-/m1/s1
Molecular Formula
C40H52F4N6O9S
HBD / HBA
3 / 15
Ikatan yang Dapat Dirotasi
9
Atom Berat
60
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
Voxilaprevir is a pan-genotypic nonstructural protein 3/4A (NS3/4A) protease inhibitor that blocks HCV protease-mediated cleavage of the viral polyprotein, preventing replication of all major hepatitis C virus genotypes. It is used in combination with sofosbuvir and velpatasvir (Vosevi) for treatment of HCV infection across genotypes 1-6, particularly in patients who have failed prior DAA therapy. Its pan-genotypic protease inhibition activity complements NS5A and NS5B inhibitors for complete HCV lifecycle blockade.
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.
Yes, Voxilaprevir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3707372. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 89921642. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="voxilaprevir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/voxilaprevir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/voxilaprevir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/voxilaprevir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="voxilaprevir"></drugfyi-drug>